Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8947577 | 0.85 | — | — | |
| SCHEMBL8947911 | 0.73 | RAB9A (0.33) | TK1 | |
| SCHEMBL8947910 | 0.73 | RAB9A (0.33) | TK1 | |
| SCHEMBL1366222 | 0.69 | RAB9A (0.55) | — | |
| SCHEMBL4533210 | 0.69 | RAB9A (0.55) | — | |
| SCHEMBL5572888 | 0.69 | PTGFR (0.35) | — | |
| SCHEMBL5572887 | 0.69 | PTGFR (0.35) | — | |
| SCHEMBL12640069 | 0.69 | PTGFR (0.38) | — | |
| SCHEMBL1367132 | 0.69 | PTGFR (0.38) | — | |
| SCHEMBL1365458 | 0.69 | PTGFR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166730-B2 | Process for the preparation of prostaglandin derivatives | FINE TECH LABORATORIES, LTD (IL) | 2007-01-23 | — | — | US | claimed |
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | FINETECH LABORATORIES LTD | 2005-09-22 | — | — | US | claimed |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | FINETECH PHARMACEUTICAL LTD. (IL) | 2011-11-24 | — | — | US | disclosed |
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| US-20090163596-A1 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD. (IL) | 2009-06-25 | — | — | US | disclosed |
| US-7166730-B2 | Process for the preparation of prostaglandin derivatives | FINE TECH LABORATORIES, LTD (IL) | 2007-01-23 | — | — | US | disclosed |
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | FINETECH LABORATORIES LTD | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | PTGIS, PTGES, PTGIR | TK1 4024/4885 |
| US-20090163596-A1 | Bimatoprost crystalline form I | PTGER1, BBC3, CYP2A7 | TK1 424/4885 |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | PTGER1, BBC3, CYP2A7 | TK1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.